Cargando…
A Phase I Open‐Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26–104/RFASE in Patients with Advanced Solid Malignancies
LESSONS LEARNED: The novel therapeutic vaccine hVEGF(26–104)/RFASE was found to be safe and well tolerated in patients with cancer. hVEGF(26–104)/RFASE failed to induce seroconversion against native hVEGF(165) and, accordingly, neither a decrease in circulating vascular endothelial growth factor (VE...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873342/ https://www.ncbi.nlm.nih.gov/pubmed/33105058 http://dx.doi.org/10.1002/onco.13576 |
_version_ | 1783649363489193984 |
---|---|
author | Goedegebuure, Ruben S.A. Wentink, Madelon Q. van der Vliet, Hans J. Timmerman, Peter Griffioen, Arjan W. de Gruijl, Tanja D. Verheul, Henk M.W. |
author_facet | Goedegebuure, Ruben S.A. Wentink, Madelon Q. van der Vliet, Hans J. Timmerman, Peter Griffioen, Arjan W. de Gruijl, Tanja D. Verheul, Henk M.W. |
author_sort | Goedegebuure, Ruben S.A. |
collection | PubMed |
description | LESSONS LEARNED: The novel therapeutic vaccine hVEGF(26–104)/RFASE was found to be safe and well tolerated in patients with cancer. hVEGF(26–104)/RFASE failed to induce seroconversion against native hVEGF(165) and, accordingly, neither a decrease in circulating vascular endothelial growth factor (VEGF) levels nor clinical benefit was observed. Remarkably, hVEGF(26–104)/RFASE induced VEGF(165)‐neutralizing antibodies in a nonhuman primate model. The absence of seroconversion in human calls for caution in the interpretation of efficacy of human vaccines in nonhuman primates. BACKGROUND: Targeting vascular endothelial growth factor‐A (VEGF) is a well‐established anticancer therapy. We designed a first‐in‐human clinical trial to investigate the safety and immunogenicity of the novel vaccine hVEGF(26–104)/RFASE. METHODS: Patients with advanced solid malignancies with no standard treatment options available were eligible for this phase I study with a 3+3 dose‐escalation design. On days 0, 14, and 28, patients received intramuscular hVEGF(26–104), a truncated synthetic three‐dimensional (3D)‐structured peptide mimic covering the amino acids 26–104 of the human VEGF(165) isoform, emulsified in the novel adjuvant Raffinose Fatty Acid Sulphate Ester (RFASE), a sulpholipopolysaccharide. Objectives were to determine safety, induction of VEGF‐neutralizing antibodies, and the maximum tolerated dose. Blood was sampled to measure VEGF levels and antibody titers. RESULTS: Eighteen of 27 enrolled patients received three immunizations in six different dose‐levels up to 1,000 μg hVEGF(26–104) and 40 mg RFASE. No dose‐limiting toxicity was observed. Although in four patients an antibody titer against hVEGF(26–104) was induced (highest titer: 2.77 (10)log), neither a reduction in VEGF levels nor neutralizing antibodies against native VEGF(165) were detected. CONCLUSION: Despite having an attractive safety profile, hVEGF(26–104)/RFASE was not able to elicit seroconversions against native VEGF(165) and, consequently, did not decrease circulating VEGF levels. Deficient RFASE adjuvant activity, as well as dominant immunoreactivity toward neoepitopes, may have impeded hVEGF(26–104)/RFASE's efficacy in humans. |
format | Online Article Text |
id | pubmed-7873342 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78733422021-02-17 A Phase I Open‐Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26–104/RFASE in Patients with Advanced Solid Malignancies Goedegebuure, Ruben S.A. Wentink, Madelon Q. van der Vliet, Hans J. Timmerman, Peter Griffioen, Arjan W. de Gruijl, Tanja D. Verheul, Henk M.W. Oncologist Clinical Trial Results LESSONS LEARNED: The novel therapeutic vaccine hVEGF(26–104)/RFASE was found to be safe and well tolerated in patients with cancer. hVEGF(26–104)/RFASE failed to induce seroconversion against native hVEGF(165) and, accordingly, neither a decrease in circulating vascular endothelial growth factor (VEGF) levels nor clinical benefit was observed. Remarkably, hVEGF(26–104)/RFASE induced VEGF(165)‐neutralizing antibodies in a nonhuman primate model. The absence of seroconversion in human calls for caution in the interpretation of efficacy of human vaccines in nonhuman primates. BACKGROUND: Targeting vascular endothelial growth factor‐A (VEGF) is a well‐established anticancer therapy. We designed a first‐in‐human clinical trial to investigate the safety and immunogenicity of the novel vaccine hVEGF(26–104)/RFASE. METHODS: Patients with advanced solid malignancies with no standard treatment options available were eligible for this phase I study with a 3+3 dose‐escalation design. On days 0, 14, and 28, patients received intramuscular hVEGF(26–104), a truncated synthetic three‐dimensional (3D)‐structured peptide mimic covering the amino acids 26–104 of the human VEGF(165) isoform, emulsified in the novel adjuvant Raffinose Fatty Acid Sulphate Ester (RFASE), a sulpholipopolysaccharide. Objectives were to determine safety, induction of VEGF‐neutralizing antibodies, and the maximum tolerated dose. Blood was sampled to measure VEGF levels and antibody titers. RESULTS: Eighteen of 27 enrolled patients received three immunizations in six different dose‐levels up to 1,000 μg hVEGF(26–104) and 40 mg RFASE. No dose‐limiting toxicity was observed. Although in four patients an antibody titer against hVEGF(26–104) was induced (highest titer: 2.77 (10)log), neither a reduction in VEGF levels nor neutralizing antibodies against native VEGF(165) were detected. CONCLUSION: Despite having an attractive safety profile, hVEGF(26–104)/RFASE was not able to elicit seroconversions against native VEGF(165) and, consequently, did not decrease circulating VEGF levels. Deficient RFASE adjuvant activity, as well as dominant immunoreactivity toward neoepitopes, may have impeded hVEGF(26–104)/RFASE's efficacy in humans. John Wiley & Sons, Inc. 2020-11-19 2021-02 /pmc/articles/PMC7873342/ /pubmed/33105058 http://dx.doi.org/10.1002/onco.13576 Text en © 2020 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Clinical Trial Results Goedegebuure, Ruben S.A. Wentink, Madelon Q. van der Vliet, Hans J. Timmerman, Peter Griffioen, Arjan W. de Gruijl, Tanja D. Verheul, Henk M.W. A Phase I Open‐Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26–104/RFASE in Patients with Advanced Solid Malignancies |
title | A Phase I Open‐Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26–104/RFASE in Patients with Advanced Solid Malignancies |
title_full | A Phase I Open‐Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26–104/RFASE in Patients with Advanced Solid Malignancies |
title_fullStr | A Phase I Open‐Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26–104/RFASE in Patients with Advanced Solid Malignancies |
title_full_unstemmed | A Phase I Open‐Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26–104/RFASE in Patients with Advanced Solid Malignancies |
title_short | A Phase I Open‐Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26–104/RFASE in Patients with Advanced Solid Malignancies |
title_sort | phase i open‐label clinical trial evaluating the therapeutic vaccine hvegf26–104/rfase in patients with advanced solid malignancies |
topic | Clinical Trial Results |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873342/ https://www.ncbi.nlm.nih.gov/pubmed/33105058 http://dx.doi.org/10.1002/onco.13576 |
work_keys_str_mv | AT goedegebuurerubensa aphaseiopenlabelclinicaltrialevaluatingthetherapeuticvaccinehvegf26104rfaseinpatientswithadvancedsolidmalignancies AT wentinkmadelonq aphaseiopenlabelclinicaltrialevaluatingthetherapeuticvaccinehvegf26104rfaseinpatientswithadvancedsolidmalignancies AT vandervliethansj aphaseiopenlabelclinicaltrialevaluatingthetherapeuticvaccinehvegf26104rfaseinpatientswithadvancedsolidmalignancies AT timmermanpeter aphaseiopenlabelclinicaltrialevaluatingthetherapeuticvaccinehvegf26104rfaseinpatientswithadvancedsolidmalignancies AT griffioenarjanw aphaseiopenlabelclinicaltrialevaluatingthetherapeuticvaccinehvegf26104rfaseinpatientswithadvancedsolidmalignancies AT degruijltanjad aphaseiopenlabelclinicaltrialevaluatingthetherapeuticvaccinehvegf26104rfaseinpatientswithadvancedsolidmalignancies AT verheulhenkmw aphaseiopenlabelclinicaltrialevaluatingthetherapeuticvaccinehvegf26104rfaseinpatientswithadvancedsolidmalignancies AT goedegebuurerubensa phaseiopenlabelclinicaltrialevaluatingthetherapeuticvaccinehvegf26104rfaseinpatientswithadvancedsolidmalignancies AT wentinkmadelonq phaseiopenlabelclinicaltrialevaluatingthetherapeuticvaccinehvegf26104rfaseinpatientswithadvancedsolidmalignancies AT vandervliethansj phaseiopenlabelclinicaltrialevaluatingthetherapeuticvaccinehvegf26104rfaseinpatientswithadvancedsolidmalignancies AT timmermanpeter phaseiopenlabelclinicaltrialevaluatingthetherapeuticvaccinehvegf26104rfaseinpatientswithadvancedsolidmalignancies AT griffioenarjanw phaseiopenlabelclinicaltrialevaluatingthetherapeuticvaccinehvegf26104rfaseinpatientswithadvancedsolidmalignancies AT degruijltanjad phaseiopenlabelclinicaltrialevaluatingthetherapeuticvaccinehvegf26104rfaseinpatientswithadvancedsolidmalignancies AT verheulhenkmw phaseiopenlabelclinicaltrialevaluatingthetherapeuticvaccinehvegf26104rfaseinpatientswithadvancedsolidmalignancies |